Taeck-Hyun Jeong, Young-Jin Son, Han-Bong Ryu, Bon-Kyung Koo, Seung-Mi Jeong, Phuong Hoang, Bich Hang Do, Jung-A Song, Seon-Ha Chong, Robert Charles Robinson, Han Choe, Soluble expression and partial purification of recombinant human erythropoietin from E. coli, Protein Expression and Purification, Volume 95, March 2014, Pages 211-218, ISSN 1046-5928, http://dx.doi.org/10.1016/j.pep.2014.01.001. (http://www.sciencedirect.com/science/article/pii/S1046592814000035)
Abstract:
Human erythropoietin (hEpo) is an essential regulator of erythrocyte production that induces the division and differentiation of erythroid progenitor cells in the bone marrow into mature erythrocytes. It is widely used for the treatment of anemia resulting from chronic kidney disease, chemotherapy, and cancer-related therapies. Active hEpo, and hEpo analogs, have been purified primarily from mammalian cells, which has several disadvantages, including low yields and high production costs. Although an Escherichia coli (E. coli) expression system may provide economic production of therapeutic proteins, it has not been used for the production of recombinant hEpo (rhEpo) because it aggregates in inclusion bodies in the E. coli cytoplasm and is not modified post-translationally. We investigated the soluble overexpression of active rhEpo with various protein tags in E. coli, and found out that several tags increased the solubility of rhEpo. Among them maltose binding protein (MBP)-tagged rhEpo was purified using affinity and gel filtration columns. Non-denaturing electrophoresis and MALDI-TOF MS analysis demonstrated that the purified rhEpo had two intra-disulfide bonds identical to those of the native hEpo. An in vitro proliferation assay showed that rhEpo purified from E. coli had similar biological activity as rhEpo derived from CHO cells. Therefore, we report for the first time that active rhEpo was overexpressed as a soluble form in the cytoplasm of E. coli and purified it in simple purification steps. We hope that our results offer opportunities for progress in rhEpo therapeutics.